Necessity of TSH Suppression Therapy in Active Surveillance for Thyroid Cancer Patients.

Sponsor
National Cancer Center, Korea
Study ID
NCT06971965
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Papillary Thyroid Carcinoma
  • Thyroid Cancer

Eligibility Criteria

Sex
ALL
Age
19 Years - 79 Years
Healthy Volunteers
Not accepted

Interventions

  • Levothyroxin — DRUG
    During the five-year study intervention period, thyroid hormone (oral administration) supplementary doses are determined according to a dose-adjustment protocol established for the group's target TSH range.

Study Details

This study is a multicenter randomized controlled trial conducted in Korea. A parallel, two-group randomized design will be with thyroid stimulating hormone suppression therapy group(low TSH group; intervention) is different from the wIthout thyroid stimulating hormone (TSH) suppression therapy group(high TSH group; control).

Key Dates

First listed
May 14, 2025
Start date
Jun 2, 2025
Status verified
May 2025
Primary completion
Dec 31, 2027
Completion
Dec 31, 2032

Study Design

Enrollment
578 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH

Arms

  • Experimental: low TSH group
    0.3 ≤ target TSH \<2.0mIU/L
  • Experimental: high TSH group
    2.0 ≤ target TSH \<8.0mIU/L

Primary Outcome Measure

Rate of Disease progression [ Time Frame: at 3,5years after enrollment ]

Central Contacts

Related Studies